The Intellectual Property (IP) of Biosceptre is comprised of products and processes related to the non-functional form of the P2X7 receptor. Biosceptre has developed various antibodies that bind with high specificity to this target. The patented use of the target and associated antibodies includes, but is not limited to, diagnostic products and processes for the detection of various cancers and products and processes for the treatment of various cancers in humans and other mammals.
Maintaining a strong patent portfolio is an integral part of the strategic positioning of Biosceptre in the oncology field. Biosceptre has established an extensive international patent portfolio that provides both broad protection of the target and specific protection of various antibody products and processes until 2032. Biosceptre will continue to protect through international patents further findings around the P2X7 receptor and use of this receptor in diagnostic, imaging and therapeutic applications.